Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction ...

This article was reviewed by Lynn Marie Morski, MD, JD. Key Takeaways: You can take Mounjaro at any time of day. The best ...

Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced topline results from the 36-week induction treatment ...

Now there is evidence that Hympavzi is also effective for people with hemophilia A and B who have developed inhibitors, a ...

The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...

Nodule and lipoma formation can occur rarely after an intramuscular influenza vaccination, particularly when administered ...

Altimmune ($ALT) announced an update on their ongoing clinical study. Altimmune’s IMPACT trial, officially titled “A Phase 2, Multicenter, ...

HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has won U.S. Food and Drug Administration approval for RYBREVANT FASPRO, the ...

Repeated insulin shots at the same site can seed amyloid; consider this diagnosis if absorption seems erratic or glucose control worsens with a persistent lump.

It is expected that Herjuema, Celltrion's anticancer drug, will be able to be administered as a subcutaneous (SC) injection in under five minutes. Celltrion said on Dec. 8 that it plans to submit ...

The US FDA approved 46 new drugs in 2025, despite a tumultuous year at the regulatory agency.

The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...